| 来源类型 | Working Paper
|
| 规范类型 | 报告
|
| DOI | 10.3386/w18552
|
| 来源ID | Working Paper 18552
|
| The Effect of Pharmaceutical Innovation on Longevity: Patient-Level Evidence from the 1996-2002 Medical Expenditure Panel Survey and Linked Mortality Public-Use Files |
| Frank R. Lichtenberg
|
| 发表日期 | 2012-11-21
|
| 出版年 | 2012
|
| 语种 | 英语
|
| 摘要 | We investigate the effect of the vintage (year of FDA approval) of the prescription drugs used by an individual on his or her survival and medical expenditure. When we only control for age, sex, and interview year, we estimate that a one-year increase in drug vintage increases life expectancy by 0.52%. Controlling for other variables including activity limitations, race, education, family income as a percent of the poverty line, insurance coverage, Census region, BMI, smoking and over 100 medical conditions has virtually no effect on the estimate of the effect of drug vintage on life expectancy. |
| 主题 | Health, Education, and Welfare
; Health
; Labor Economics
; Demography and Aging
; Development and Growth
; Innovation and R&
; D
|
| URL | https://www.nber.org/papers/w18552
|
| 来源智库 | National Bureau of Economic Research (United States)
|
| 引用统计 |
|
| 资源类型 | 智库出版物
|
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/576227
|
推荐引用方式
GB/T 7714 |
Frank R. Lichtenberg. The Effect of Pharmaceutical Innovation on Longevity: Patient-Level Evidence from the 1996-2002 Medical Expenditure Panel Survey and Linked Mortality Public-Use Files. 2012.
|
|
文件名：
|
w18552.pdf
|
|
格式：
|
Adobe PDF
|
此文件暂不支持浏览
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
